CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical safety rating: safe
May enhance the effects of neuromuscular blocking agents Causes severe and sometimes fatal Clostridium difficile-associated diarrhea.
Reversibly binds to the 50S subunit of bacterial ribosomes, inhibiting peptide bond formation and protein synthesis. May also act as a bacterial protein synthesis inhibitor by dissociating ribosomes.
| Metabolism | Primarily hepatic via CYP3A4 and possibly other cytochrome P450 enzymes. Metabolites include N-demethylclindamycin and sulfoxide derivatives. |
| Excretion | Clindamycin is primarily excreted via bile and feces (approximately 90% as metabolites), with renal elimination accounting for about 10% (parent drug and N-demethylated metabolite). Less than 1% is excreted unchanged in urine. |
| Half-life | The terminal elimination half-life is approximately 2.4 hours in adults with normal renal function, but increases to 3-5 hours in patients with severe hepatic impairment. Renal impairment has minimal effect. In neonates, half-life may be prolonged (up to 8-12 hours). |
| Protein binding | Clindamycin is 60-95% bound to plasma proteins (primarily albumin). Binding is concentration-dependent and decreases at higher concentrations. |
| Volume of Distribution | The volume of distribution is approximately 0.6-1.2 L/kg (average 0.7 L/kg), indicating extensive tissue penetration. It distributes into most body tissues and fluids, including bone, abscesses, and cerebrospinal fluid (only when meninges are inflamed). |
| Bioavailability | Oral: Approximately 90% (rapidly absorbed; food does not significantly affect absorption). IM: Complete absorption. IV: 100% bioavailable. |
| Onset of Action | Intravenous: Rapid, within minutes after infusion. Intramuscular: 1-2 hours. Oral: 1-2 hours. |
| Duration of Action | Approximately 6-8 hours for IV/IM dosing (every 6-8 hour dosing interval). Oral dosing provides similar duration. Note: For anaerobic infections, longer intervals (every 12 hours) may be used for convenience but efficacy data support every 6-8 hours. |
Adult: 300-600 mg IV every 6-8 hours, up to 2.7 g/day in 3-4 divided doses for severe infections.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for GFR >30 mL/min; for GFR <30 mL/min, use normal dose but extend interval to every 12-24 hours or consider alternative due to potential toxicity. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: reduce dose by 50-75% and monitor hepatic function. |
| Pediatric use | Children: 10-40 mg/kg/day IV divided every 6-8 hours (max 2.7 g/day); neonates: 15-20 mg/kg/day IV divided every 8-12 hours. |
| Geriatric use | Elderly: no specific dose adjustment required, but monitor renal function and consider reduced clearance due to age-related renal decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
May enhance the effects of neuromuscular blocking agents Causes severe and sometimes fatal Clostridium difficile-associated diarrhea.
| FDA category | Human |
| Breastfeeding | Clindamycin is excreted in human milk in low amounts; the milk-to-plasma ratio is approximately 0.1 to 0.4. No adverse effects on breastfeeding infants have been reported. Caution is advised, and use only if necessary. |
| Teratogenic Risk | Clindamycin phosphate is classified as FDA Pregnancy Category B. Animal reproduction studies have not demonstrated fetal risk, but no adequate and well-controlled studies in pregnant women exist. First trimester: No evidence of teratogenicity; second and third trimesters: considered safe for use. However, use only if clearly needed. |
■ FDA Black Box Warning
Clindamycin can cause severe and sometimes fatal colitis (including pseudomembranous colitis) due to Clostridium difficile overgrowth. Discontinue use if significant diarrhea occurs.
| Common Effects | Diarrhea (including C. difficile) |
| Serious Effects |
["Hypersensitivity to clindamycin, lincomycin, or any component of the formulation","History of antibiotic-associated colitis or inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease)"]
| Precautions | ["Risk of Clostridium difficile-associated diarrhea (CDAD) and pseudomembranous colitis","May cause severe hypersensitivity reactions including anaphylaxis and Stevens-Johnson syndrome","Neuromuscular blocking effects may potentiate other neuromuscular blocking agents","Prolonged use may result in overgrowth of nonsusceptible organisms (superinfection)","Renal and hepatic impairment may require dose adjustment"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal liver function, renal function, and complete blood count periodically during prolonged therapy. Observe the neonate for potential gastrointestinal disturbances (e.g., diarrhea, colitis). No specific fetal monitoring required. |
| Fertility Effects | No known adverse effects on fertility. Animal studies have not shown impaired fertility. |